SEARCH

SEARCH BY CITATION

LITERATURE CITED

  • Adachi S, Ogasawara T, Tsubamoto H, Oku H, Hori Y, Tsuji Y, Takemura T, Koyama K. 2001. Intravenous nedaplatin and intraarterial cisplatin with transcatheter arterial embolization for patients with locally advanced uterine cervical cancer. Int J Clin Pharmacol Res 21: 105110.
  • Aggarwal SK, Fadool JM. 1993. Cisplatin and carboplatin induced changes in the neurohypophysis and parathyroid, and their role in nephrotoxicity. Anticancer Drugs 4: 149162.
  • Alberts DS. 1995. Carboplatin versus cisplatin in ovarian cancer. Semin Oncol 22: 8890.
  • Bauer CA, Turner JG, Caspary DM, Myers KS, Brozoski TJ. 2008. Tinnitus and inferior colliculus activity in chinchillas related to three distinct patterns of cochlear trauma. J Neurosci Res 86: 25642578.
  • Berlin CI, Hood LJ, Morlet T, Wilensky D, Li L, Mattingly KR, Taylor-Jeanfreau J, Keats BJ, John PS, Montgomery E, Shallop JK, Russell BA, Frisch SA. 2010. Multi-site diagnosis and management of 260 patients with auditory neuropathy/dys-synchrony (auditory neuropathy spectrum disorder). Int J Audiol 49: 3043.
  • Blair BG, Larson CA, Safaei R, Howell SB. 2009. Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin. Clin Cancer Res 15: 43124321.
  • Boulikas T, Vougiouka M. 2003. Cisplatin and platinum drugs at the molecular level. Oncol Rep 10: 16631682.
  • Campbell KC, Rybak LP, Meech RP, Hughes L. 1996. D-methionine provides excellent protection from cisplatin ototoxicity in the rat. Hear Res 102: 9098.
  • Cardinaal RM, de Groot JC, Huizing EH, Veldman JE, Smoorenburg GF. 2000. Dose-dependent effect of 8-day cisplatin administration upon the morphology of the albino guinea pig cochlea. Hear Res 144: 135146.
  • Cavaletti G, Bogliun G, Crespi V, Marzorati L, Zincone A, Marzola M, Rota S, Galli A, Tredici P, Tredici G. 1997. Neurotoxicity and ototoxicity of cisplatin plus paclitaxel in comparison to cisplatin plus cyclophosphamide in patients with epithelial ovarian cancer. J Clin Oncol 15: 199206.
  • Cheng AG, Huang T, Stracher A, Kim A, Liu W, Malgrange B, Lefebvre PP, Schulman A, Van de Water TR. 1999. Calpain inhibitors protect auditory sensory cells from hypoxia and neurotrophin-withdrawal induced apoptosis. Brain Res 850: 234243.
  • Chollet P, Bensmaine MA, Brienza S, Deloche C, Cure H, Caillet H, Cvitkovic E. 1996. Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann Oncol 7: 10651070.
  • Ciarimboli G, Deuster D, Knief A, Sperling M, Holtkamp M, Edemir B, Pavenstadt H, Lanvers-Kaminsky C, am Zehnhoff-Dinnesen A, Schinkel AH, Koepsell H, Jurgens H, Schlatter E. 2010. Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. Am J Pathol 176: 11691180.
  • Clerici WJ, Hensley K, DiMartino DL, Butterfield DA. 1996. Direct detection of ototoxicant-induced reactive oxygen species generation in cochlear explants. Hear Res 98: 116124.
  • Coling DE, Ding D, Young R, Lis M, Stofko E, Blumenthal KM, Salvi RJ. 2007. Proteomic analysis of cisplatin-induced cochlear damage: methods and early changes in protein expression. Hear Res 226: 140156.
  • Devarajan P, Savoca M, Castaneda MP, Park MS, Esteban-Cruciani N, Kalinec G, Kalinec F. 2002. Cisplatin-induced apoptosis in auditory cells: role of death receptor and mitochondrial pathways. Hear Res 174: 4554.
  • Ding D, Allman BL, Yin S, Sun H, Salvi R. 2011a. Cisplatin ototoxicity. In: Dupont J, editor. Hearing loss: classification, causes and treatment. Hauggauge, NY: Nova Science. p 3963.
  • Ding D, He J, Allman BL, Yu D, Jiang H, Seigel GM, Salvi RJ. 2011b. Cisplatin ototoxicity in rat cochlear organotypic cultures. Hear Res 282: 192203.
  • Ding D, Jiang H, Wang P, Salvi R. 2007. Cell death after co-administration of cisplatin and ethacrynic acid. Hear Res 226: 129139.
  • Ding D, McFadden SL, Salvi RJ. 2001. Cochlear hair cell densities and inner ear staining techniques. In: Willott J, editor. The auditory psychobiology of the mouse. Boca Raton: CRC Press. p 189204.
  • Ding D, Wang J, Yu Z, Jiang H, Wang P, Salvi R. 2008. Spontaneous proliferation in organotypic cultures of mouse cochlea. J Otol 3: 7683.
  • Ding DL, Wang J, Salvi R, Henderson D, Hu BH, McFadden SL, Mueller M. 1999. Selective loss of inner hair cells and type-I ganglion neurons in carboplatin-treated chinchillas. Mechanisms of damage and protection. Ann N Y Acad Sci 884: 152170.
  • Fernandez-Cervilla F, Crespo PV, Ciges M, Campos A. 1993. Early morphofunctional alterations induced by cisplatin in the cochlea. A quantitative and electrocochleographic study. ORL J Otorhinolaryngol Relat Spec 55: 337340.
  • Forge A. 1981. Electron microscopy of the stria vascularis and its response to ethacrynic acid. A study using electron-dense tracers and extracellular surface markers. Audiology 20: 273289.
  • Forge A, Brown AM. 1982. Ultrastructural and electrophysiological studies of acute ototoxic effects of furosemide. Br J Audiol 16: 109116.
  • Garcia-Berrocal JR, Nevado J, Ramirez-Camacho R, Sanz R, Gonzalez-Garcia JA, Sanchez-Rodriguez C, Cantos B, Espana P, Verdaguer JM, Trinidad Cabezas A. 2007. The anticancer drug cisplatin induces an intrinsic apoptotic pathway inside the inner ear. Br J Pharmacol 152: 10121020.
  • Geoerger B, Doz F, Gentet JC, Mayer M, Landman-Parker J, Pichon F, Chastagner P, Rubie H, Frappaz D, Le Bouil A, Gupta S, Vassal G. 2008. Phase I study of weekly oxaliplatin in relapsed or refractory pediatric solid malignancies. J Clin Oncol 26: 43944400.
  • Giordano P, Lorito G, Ciorba A, Martini A, Hatzopoulos S. 2006. Protection against cisplatin ototoxicity in a Sprague-Dawley rat animal model. Acta Otorhinolaryngol Ital 26: 198207.
  • Gratton MA, Salvi RJ, Kamen BA, Saunders SS. 1990. Interaction of cisplatin and noise on the peripheral auditory system. Hear Res 50: 211223.
  • Gregg RW, Molepo JM, Monpetit VJ, Mikael NZ, Redmond D, Gadia M, Stewart DJ. 1992. Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol 10: 795803.
  • Haller DG. 2000. Safety of oxaliplatin in the treatment of colorectal cancer. Oncology (Williston Park) 14: 1520.
  • Hannigan EV, Green S, Alberts DS, O'Toole R, Surwit E. 1993. Results of a Southwest Oncology Group phase III trial of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide in advanced ovarian cancer. Oncology 50( Suppl 2): 29.
  • He J, Yin S, Wang J, Ding D, Jiang H. 2009. Effectiveness of different approaches for establishing cisplatin-induced cochlear lesions in mice. Acta Otolaryngol 129: 13591367.
  • Hellberg V, Wallin I, Eriksson S, Hernlund E, Jerremalm E, Berndtsson M, Eksborg S, Arner ES, Shoshan M, Ehrsson H, Laurell G. 2009. Cisplatin and oxaliplatin toxicity: importance of cochlear kinetics as a determinant for ototoxicity. J Natl Cancer Inst 101: 3747.
  • Henderson D, Bielefeld EC, Harris KC, Hu BH. 2006. The role of oxidative stress in noise-induced hearing loss. Ear Hear 27: 119.
  • Hill GW, Morest DK, Parham K. 2008. Cisplatin-induced ototoxicity: effect of intratympanic dexamethasone injections. Otol Neurotol 29: 10051011.
  • Hirose K, Sato E. 2010. Comparative analysis of combination kanamycin-furosemide versus kanamycin alone in the mouse cochlea. Hear Res 272: 108116.
  • Hofstetter P, Ding D, Salvi R. 1997. Magnitude and pattern of inner and outer hair cell loss in chinchilla as a function of carboplatin dose. Audiology 36: 301311.
  • Holzer AK, Katano K, Klomp LW, Howell SB. 2004. Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells. Clin Cancer Res 10: 67446749.
  • Horiuchi M, Miyake H, Ota K. 1992. Ototoxicity of cis-diammine glycolato platinum, 254-S. Gan To Kagaku Ryoho 19: 13271332.
  • Howell SB, Safaei R, Larson CA, Sailor MJ. 2010. Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs. Mol Pharmacol 77: 887894.
  • Husain K, Scott RB, Whitworth C, Somani SM, Rybak LP. 2001a. Dose response of carboplatin-induced hearing loss in rats: antioxidant defense system. Hear Res 151: 7178.
  • Husain K, Whitworth C, Somani SM, Rybak LP. 2001b. Carboplatin-induced oxidative stress in rat cochlea. Hear Res 159: 1422.
  • Husmann KR, Morgan AS, Girod DA, Durham D. 1998. Round window administration of gentamicin: a new method for the study of ototoxicity of cochlear hair cells. Hear Res 125: 109119.
  • Ito K, Adachi S, Itani Y, Koyama M, Hori K, Chin R, Shintani M, Beppu K, Kawai S, Saito K. 1999. A dose-finding study of nedaplatin and cyclophosphamide for patients with gynecological malignancies. Jpn J Clin Oncol 29: 299302.
  • Jacono AA, Hu B, Kopke RD, Henderson D, Van De Water TR, Steinman HM. 1998. Changes in cochlear antioxidant enzyme activity after sound conditioning and noise exposure in the chinchilla. Hear Res 117: 3138.
  • Jamesdaniel S, Ding D, Kermany MH, Davidson BA, Knight PR, III, Salvi R, Coling DE. 2008. Proteomic analysis of the balance between survival and cell death responses in cisplatin-mediated ototoxicity. J Proteome Res 7: 35163524.
  • Jamesdaniel S, Hu B, Kermany MH, Jiang H, Ding D, Coling D, Salvi R. 2011. Noise induced changes in the expression of p38/MAPK signaling proteins in the sensory epithelium of the inner ear. J Proteomics 75: 410424.
  • Juhn SK, Rybak LP, Prado S. 1981. Nature of blood-labyrinth barrier in experimental conditions. Ann Otol Rhinol Laryngol 90: 135141.
  • Kimitsuki T, Nakagawa T, Hisashi K, Komune S, Komiyama S. 1993. Cisplatin blocks mechano-electric transducer current in chick cochlear hair cells. Hear Res 71: 6468.
  • Komune S, Snow JB, Jr. 1981. Potentiating effects of cisplatin and ethacrynic acid in ototoxicity. Arch Otolaryngol 107: 594597.
  • Kosugi S, Kanda T, Nakagawa S, Ohashi M, Nishimaki T, Hatakeyama K. 2005. Efficacy and toxicity of fluorouracil, doxorubicin, and cisplatin/nedaplatin treatment as neoadjuvant chemotherapy for advanced esophageal carcinoma. Scand J Gastroenterol 40: 886892.
  • Larson CA, Blair BG, Safaei R, Howell SB. 2009. The role of the mammalian copper transporter 1 in the cellular accumulation of platinum-based drugs. Mol Pharmacol 75: 324330.
  • Lautermann J, Crann SA, McLaren J, Schacht J. 1997. Glutathione-dependent antioxidant systems in the mammalian inner ear: effects of aging, ototoxic drugs and noise. Hear Res 114: 7582.
  • Li G, Sha SH, Zotova E, Arezzo J, Van de Water T, Schacht J. 2002. Salicylate protects hearing and kidney function from cisplatin toxicity without compromising its oncolytic action. Lab Invest 82: 585596.
  • Li H, Wang Q, Steyger PS. 2011a. Acoustic trauma increases cochlear and hair cell uptake of gentamicin. PLoS One 6: e19130.
  • Li M, Ding D, Zheng X, Salvi RJ. 2004. Vestibular destruction by slow infusion of gentamicin into semicircular canals. Acta Otolaryngol 552: 17.
  • Li Y, Ding D, Jiang H, Fu Y, Salvi R. 2011b. Co-administration of cisplatin and furosemide causes rapid and massive loss of cochlear hair cells in mice. Neurotox Res 20: 307319.
  • Liu W, Staecker H, Stupak H, Malgrange B, Lefebvre P, Van De Water TR. 1998. Caspase inhibitors prevent cisplatin-induced apoptosis of auditory sensory cells. Neuroreport 9: 26092614.
  • Lucas JH, Wheeler DG, Emery DG, Mallery SR. 1998. The endogenous antioxidant glutathione as a factor in the survival of physically injured mammalian spinal cord neurons. J Neuropathol Exp Neurol 57: 937954.
  • Madden C, Rutter M, Hilbert L, Greinwald JH, Jr., Choo DI. 2002. Clinical and audiological features in auditory neuropathy. Arch Otolaryngol Head Neck Surg 128: 10261030.
  • Malhotra NK, Aslam R, Lipman SP, Bilski VJ. 2010. Acute ototoxicity from a single infusion of oxaliplatin. Ear Nose Throat J 89: 258261.
  • Mangala LS, Zuzel V, Schmandt R, Leshane ES, Halder JB, Armaiz-Pena GN, Spannuth WA, Tanaka T, Shahzad MM, Lin YG, Nick AM, Danes CG, Lee JW, Jennings NB, Vivas-Mejia PE, Wolf JK, Coleman RL, Siddik ZH, Lopez-Berestein G, Lutsenko S, Sood AK. 2009. Therapeutic targeting of ATP7B in ovarian carcinoma. Clin Cancer Res 15: 37703780.
  • Meyers JR, MacDonald RB, Duggan A, Lenzi D, Standaert DG, Corwin JT, Corey DP. 2003. Lighting up the senses: FM1-43 loading of sensory cells through nonselective ion channels. J Neurosci 23: 40544065.
  • Minami SB, Sha SH, Schacht J. 2004. Antioxidant protection in a new animal model of cisplatin-induced ototoxicity. Hear Res 198: 137143.
  • Minowa Y. 1984. Sensorineural hearing impairment by combined administration of aminoglycoside drugs, loop diuretics and an anticancer drug (cisplatin)—an experimental study. Nihon Jibiinkoka Gakkai Kaiho 87: 202212.
  • More SS, Akil O, Ianculescu AG, Geier EG, Lustig LR, Giacomini KM. 2010. Role of the copper transporter, CTR1, in platinum-induced ototoxicity. J Neurosci 30: 95009509.
  • Muller M, Smolders JW. 2005. Shift in the cochlear place-frequency map after noise damage in the mouse. Neuroreport 16: 11831187.
  • Neuwelt EA, Glasberg M, Frenkel E, Barnett P. 1983. Neurotoxicity of chemotherapeutic agents after blood-brain barrier modification: neuropathological studies. Ann Neurol 14: 316324.
  • O'Dwyer PJ, Stevenson JP, Johnson SW. 2000. Clinical pharmacokinetics and administration of established platinum drugs. Drugs 59( Suppl 4): 1927.
  • Oesterle EC, Campbell S, Taylor RR, Forge A, Hume CR. 2008. Sox2 and JAGGED1 expression in normal and drug-damaged adult mouse inner ear. J Assoc Res Otolaryngol 9: 6589.
  • Ohashi T, Ohnishi M, Tanahashi S, Murai M. 2011. Efficacy and toxicity of concurrent chemoradiotherapy with nedaplatin and S-1 for head and neck cancer. Jpn J Clin Oncol 41: 348352.
  • Ohlemiller KK, Wright JS, Dugan LL. 1999. Early elevation of cochlear reactive oxygen species following noise exposure. Audiol Neurootol 4: 229236.
  • Oldenburg J, Kraggerud SM, Cvancarova M, Lothe RA, Fossa SD. 2007. Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors. J Clin Oncol 25: 708714.
  • Park CM, Park MJ, Kwak HJ, Moon SI, Yoo DH, Lee HC, Park IC, Rhee CH, Hong SI. 2006. Induction of p53-mediated apoptosis and recovery of chemosensitivity through p53 transduction in human glioblastoma cells by cisplatin. Int J Oncol 28: 119125.
  • Pasetto LM, D'Andrea MR, Rossi E, Monfardini S. 2006. Oxaliplatin-related neurotoxicity: how and why? Crit Rev Oncol Hematol 59: 159168.
  • Peters U, Preisler-Adams S, Lanvers-Kaminsky C, Jurgens H, Lamprecht-Dinnesen A. 2003. Sequence variations of mitochondrial DNA and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Res 23: 12491255.
  • Piccart MJ, Lamb H, Vermorken JB. 2001. Current and future potential roles of the platinum drugs in the treatment of ovarian cancer. Ann Oncol 12: 11951203.
  • Poirrier AL, Van den Ackerveken P, Kim TS, Vandenbosch R, Nguyen L, Lefebvre PP, Malgrange B. 2010. Ototoxic drugs: difference in sensitivity between mice and guinea pigs. Toxicol Lett 193: 4149.
  • Qi W, Ding D, Salvi RJ. 2008. Cytotoxic effects of dimethyl sulphoxide (DMSO) on cochlear organotypic cultures. Hear Res 236: 5260.
  • Ravi R, Somani SM, Rybak LP. 1995. Mechanism of cisplatin ototoxicity: antioxidant system. Pharmacol Toxicol 76: 386394.
  • Reyes S, Ding D, Sun W, Salvi R. 2001. Effect of inner and outer hair cell lesions on electrically evoked otoacoustic emissions. Hear Res 158: 139150.
  • Ryan AF, Bone RC. 1978. Potentiation of kanamycin ototoxicity by a history of noise exposure. Otolaryngology 86: ORL-125128.
  • Ryan AF, Bone RC. 1982. Non-simultaneous interaction of exposure to noise and kanamycin intoxication in the chinchilla. Am J Otolaryngol 3: 264272.
  • Rybak LP. 1985. Furosemide ototoxicity: clinical and experimental aspects. Laryngoscope 95: 114.
  • Rybak LP. 1993. Ototoxicity of loop diuretics. Otolaryngol Clin North Am 26: 829844.
  • Saito T, Saito H, Saito K, Wakui S, Manabe Y, Tsuda G. 1989. Ototoxicity of carboplatin in guinea pigs. Auris Nasus Larynx 16: 1321.
  • Samimi G, Safaei R, Katano K, Holzer AK, Rochdi M, Tomioka M, Goodman M, Howell SB. 2004. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells. Clin Cancer Res 10: 46614669.
  • Shi X, Nuttall AL. 2003. Upregulated iNOS and oxidative damage to the cochlear stria vascularis due to noise stress. Brain Res 967: 110.
  • Shiozaki A, Miyazaki H, Niisato N, Nakahari T, Iwasaki Y, Itoi H, Ueda Y, Yamagishi H, Marunaka Y. 2006. Furosemide, a blocker of Na+/K+/2Cl- cotransporter, diminishes proliferation of poorly differentiated human gastric cancer cells by affecting G0/G1 state. J Physiol Sci 56: 401406.
  • Sockalingam R, Freeman S, Cherny TL, Sohmer H. 2000. Effect of high-dose cisplatin on auditory brainstem responses and otoacoustic emissions in laboratory animals. Am J Otol 21: 521527.
  • Syka J, Melichar I. 1981. Comparison of the effects of furosemide and ethacrynic acid upon the cochlear function in the guinea pig. Scand Audiol Suppl 14: 6369.
  • Takeno S, Harrison RV, Mount RJ, Wake M, Harada Y. 1994. Induction of selective inner hair cell damage by carboplatin. Scanning Microsc 8: 97106.
  • Taudy M, Syka J, Popelar J, Ulehlova L. 1992. Carboplatin and cisplatin ototoxicity in guinea pigs. Audiology 31: 293299.
  • Teeling M, Carney DN. 1990. Phase II study of carboplatin and cyclophosphamide combination chemotherapy for the treatment of advanced ovarian cancer. Eur J Gynaecol Oncol 11: 219224.
  • Tran Ba Huy P, Manuel C, Meulemans A, Sterkers O, Wassef M, Amiel C. 1983. Ethacrynic acid facilitates gentamicin entry into endolymph of the rat. Hear Res 11: 191202.
  • Trautwein P, Hofstetter P, Wang J, Salvi R, Nostrant A. 1996. Selective inner hair cell loss does not alter distortion product otoacoustic emissions. Hear Res 96: 7182.
  • Uehara T, Watanabe H, Itoh F, Inoue S, Koshida H, Nakamura M, Yamate J, Maruyama T. 2005. Nephrotoxicity of a novel antineoplastic platinum complex, nedaplatin: a comparative study with cisplatin in rats. Arch Toxicol 79: 451460.
  • Vlajkovic SM, Housley GD, Thorne PR. 2009. Adenosine and the auditory system. Curr Neuropharmacol 7: 246256.
  • Wake M, Takeno S, Ibrahim D, Harrison R, Mount R. 1993. Carboplatin ototoxicity: an animal model. J Laryngol Otol 107: 585589.
  • Wang J, Ding D, Salvi RJ. 2003. Carboplatin-induced early cochlear lesion in chinchillas. Hear Res 181: 6572.
  • Wang J, Powers NL, Hofstetter P, Trautwein P, Ding D, Salvi R. 1997. Effects of selective inner hair cell loss on auditory nerve fiber threshold, tuning and spontaneous and driven discharge rate. Hear Res 107: 6782.
  • Wang Q, Steyger PS. 2009. Trafficking of systemic fluorescent gentamicin into the cochlea and hair cells. J Assoc Res Otolaryngol 10: 205219.
  • Yokoo S, Yonezawa A, Masuda S, Fukatsu A, Katsura T, Inui K. 2007. Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. Biochem Pharmacol 74: 477487.
  • Yonezawa A, Inui K. 2011. Organic cation transporter OCT/SLC22A and H(+)/organic cation antiporter MATE/SLC47A are key molecules for nephrotoxicity of platinum agents. Biochem Pharmacol 81: 563568.
  • Yu D, Ding D, Jiang H, Stolzberg D, Salvi R. 2011. Mefloquine damage vestibular hair cells in organotypic cultures. Neurotox Res 20: 5158.
  • Zhang M, Liu W, Ding D, Salvi R. 2003. Pifithrin-alpha suppresses p53 and protects cochlear and vestibular hair cells from cisplatin-induced apoptosis. Neurosci 120: 191205.
  • Zhang S, Lovejoy KS, Shima JE, Lagpacan LL, Shu Y, Lapuk A, Chen Y, Komori T, Gray JW, Chen X, Lippard SJ, Giacomini KM. 2006. Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res 66: 88478857.
  • Zhou Y, Ding D, Kraus KS, Yu D, Salvi RJ. 2009. Functional and structural changes in the chinchilla cochlea and vestibular system following round window application of carboplatin. Audiol Med 7: 189199.